SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
lan
Lv1
20 积分
2020-12-31 加入
最近求助
最近应助
互助留言
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
1天前
已完结
POSing the question: MARIPOSA-2, do the ends justify the means?
1天前
已完结
Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase
2天前
已完结
NCCN CNS tumor guidelines update for 2023
13天前
已完结
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
1个月前
已完结
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
1个月前
已完结
1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions
1个月前
已完结
Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase
3个月前
已完结
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase
3个月前
已完结
Drugging RAS: Moving Beyond KRASG12C
4个月前
已完结
没有进行任何应助
感谢,感谢,感谢
1天前
感谢,感谢,感谢
1天前
感谢,感谢,感谢
2天前
感谢,感谢,感谢
3个月前
感谢,感谢,感谢
3个月前
感谢,感谢
5个月前
感谢,感谢,感谢
5个月前
感谢
5个月前
感谢,感谢,感谢,感谢
6个月前
感谢,感谢,感谢,感谢
6个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论